Company & Sponsor Intelligence

Eisai Korea Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed5

Countries1

Therapeutic footprint

alzheimersepilepsy

Indexed studies

NCT02097056Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
alzheimers · South KoreaPHASE4

NCT00165724Alzheimer's Disease Long-term Follow-up Study (ALF Study)
alzheimers · South KoreaPHASE4

NCT03448445A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
alzheimers · South KoreaCOMPLETED

NCT02158910A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
alzheimers · South KoreaCOMPLETED

NCT01140867Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
epilepsy · South KoreaPHASE4

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →